ClinicalTrials.gg
Not yet recruitingNCT07387302Updated Feb 4, 2026

SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

A Phase 2 interventional study of SLN12140 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Linno Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Linno Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140.

The study is divided into four phases: screening period, core treatment period, extended dosing period, and follow-up period, and includes two cohorts (Cohorts 1-2), with each cohort enrolling at least 5 treatment-naïve adult PNH subjects for complement inhibitor therapy.

02

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
03

In context

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

This study's planned enrollment of 10 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.

Browse Hemoglobinuria, Paroxysmal studies →

Lead sponsor

Linno Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult complement inhibitor naïve PNH patients (age>=18), which is confirmed by flow cytometry evaluation
  • Must be vaccinated against meningococcal vaccine and pneumococcal vaccine

Exclusion criteria

Exclusion Criteria:

  • Significant bone marrow failure
  • Meningitidis infection or unresolved meningococcal disease
  • Other significant systemic diseases that might have impact on efficacy and safety assessment
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    SLN 12140 will be administered subcutaneously .

    5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks. 5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks

    Drug: SLN12140

Interventions

  • 5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks. 5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks

06

What researchers measure

Primary outcomes

  1. During the 12-week treatment period, the proportion of participants whose Lactate Dehydrogenase (LDH) decreased by 60% or more from baseline or whose LDH was below the upper limit

    To assess efficacy of SLN12140 in participants with PNH

    Time frame: 12weeks after baseline

Secondary outcomes

  1. Percentage change of LDH from baseline

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through Week 64

  2. Proportion of participants achieving hemolysis control (LDH ≤ 1.5×ULN)

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through Week 64

  3. Change in hemoglobin (Hb) levels from baseline

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through week 64

  4. The proportion of participants whose hemoglobin (Hb) increased by ≥2 g/dL from baseline and who avoided blood transfusion

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through Week 64

  5. Proportion of participants who avoided blood transfusion

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through Week 64

  6. Incidence(%) of Breakthrough Hemolysis (BTH)

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through Week 64

  7. Changes from baseline in intravascular and extravascular hemolysis indicators (including but not limited to reticulocytes, bilirubin, red blood cell count, platelet count, ferritin, etc.)

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: baseline through week 64

  8. Changes in thrombus formation risk markers from baseline (including but not limited to fibrinogen, prothrombin time, activated partial thromboplastin time, thrombin time, fibrin D-dimer, etc.);

    To assess the efficacy of SLN12140 in participants with PNH

    Time frame: Baseline through week 64

  9. Change in functional assessment of Functional Assessment of Chronic Illness Therapy (FACIT)

    To assess the efficacy of SLN12140 in participants with PNH. FACIT is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function to assess the Impact of SLN12140 on Treatment-Related Outcomes. The minimum value is 0 and maximum value is 52, and higher scores mean a worse outcome.

    Time frame: Baseline through Week 64

  10. Number(%) of participants with Adverse Events (AEs) , Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of SLN12140 in participants with PNH

    Time frame: Baseline through Week 64

  11. Pharmacokinetics (PK)parameters of SLN12140: Area Under The Plasma Concentration-time Curve

    To characterize the pharmacokinetics of SLN12140 in participants with PNH

    Time frame: Baseline through week 64 (predose and postdose)

  12. Immunegenicity in Paraxysmal Nocturnal Hemoglobinuria

    Determine anti-drug antibody titers

    Time frame: Baseline through Week 64

  13. PK: Maximum Plasma Concentration (Cmax)

    To characterize the pharmacokinetics of SLN12140 in participants with PNH

    Time frame: Baseline through week 64( predose and postdose)

  14. PK: Time To Maximum Concentration (Tmax)

    To characterize the pharmacokinetics of SLN12140 in participants with PNH

    Time frame: Baseline through week 64( predose and postdose)

  15. Complement Alternative Pathway (AP) Functional Activity

    Serum AP functional activity was measured by the Wieslab functional immunoassay method.

    Time frame: Baseline through week 64( predose and post dose)

  16. Complement FP

    Plasma FP was measured by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline through week 64(predose and postdose)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — It is not decided yet at this moment if we will share IPD with other researchers, or when will IPD will be shared, or with whom will IPD be shared, or by what mechanism will IPD be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jul 2026, 5 months later.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 5 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Feb 4, 2026
StartEst.
Feb 10, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07387302
Lead sponsor
Linno Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Feb 10, 2026 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Hong Yan Tong, Professor
Contact
hongyantong@aliyun.com
86+13958122357
Feng Kui Zhang, Professor
Contact
fkzhang@ihcams.ac.cn
86+ ext. 13821700281

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLN12140

Start the discussion